NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Providence Therapeutics

Providence Therapeutics

Private
CalgaryHealthcare & Life Scienceshttps://providencetherapeutics.com/

Last Round

Grant

Dec 7, 2021

Total Funding Raised

$9.62M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Providence Therapeutics is a biotechnology company that develops messenger RNA (mRNA) medicines for cancer treatment and infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2G

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

mRNA medicinesmRNA platformcancer immunotherapypersonalized cancer vaccinelipid nanoparticle deliveryLNPinfectious disease vaccinemRNA manufacturingvaccine developmentdrug delivery systemclinical-stage biotechco-development partnershipB2G

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Providence Therapeutics Comparables

Compare Providence Therapeutics with similar companies based on industry and business-model similarity.

Providence Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
PopVax
85%
Stemirna Therapeutics
79%
Abogen Biosciences
79%

Providence Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 7, 2021
GrantJan 21, 2021
GrantOct 1, 2020

Key People

Founding team and executive leadership

Bradley Sorenson

President CEO

Executive Team

Kevin Thompson

Executive Vice President Finance & Accounting - Interim Chief Financial Officer

Executive Team

Providence Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 13, 2026

    Open roles increased to 13, 5.6x the trailing average.

  • Aug 23, 2025

    Grew 17% QoQ, from 53 to 62 employees.

Providence Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Providence Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Providence Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCalgary
Employee Range58
Year Founded2015
Last FundingDec 7, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.